Email updates

Keep up to date with the latest news and content from Virology Journal and BioMed Central.

Open Access Research

Examination of soluble integrin resistant mutants of foot-and-mouth disease virus

Paul Lawrence, Michael LaRocco, Barry Baxt and Elizabeth Rieder*

Author Affiliations

Foreign Animal Disease Research Unit, United States Department of Agriculture, Agricultural Research Service, Plum Island Animal Disease Center, PO Box 848, Greenport, NY, 11944-0848, USA

For all author emails, please log on.

Virology Journal 2013, 10:2  doi:10.1186/1743-422X-10-2

The electronic version of this article is the complete one and can be found online at: http://www.virologyj.com/content/10/1/2


Received:5 July 2012
Accepted:11 December 2012
Published:2 January 2013

© 2013 Lawrence et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Foot-and-mouth disease virus (FMDV) initiates infection via recognition of one of at least four cell-surface integrin molecules αvβ1, αvβ3, αvβ6, or αvβ8 by a highly conserved Arg-Gly-Asp (RGD) amino acid sequence motif located in the G-H loop of VP1. Within the animal host, the αvβ6 interaction is believed to be the most relevant. Sub-neutralizing levels of soluble secreted αvβ6 (ssαvβ6) was used as a selective pressure during passages in vitro to explore the plasticity of that interaction.

Results

Genetically stable soluble integrin resistant (SIR) FMDV mutants derived from A24 Cruzeiro were selected after just 3 passages in cell culture in the presence of sub-neutralizing levels of ssαvβ6. SIR mutants were characterized by: replication on selective cell lines, plaque morphology, relative sensitivity to ssαvβ6 neutralization, relative ability to utilize αvβ6 for infection, as well as sequence and structural changes. All SIR mutants maintained an affinity for αvβ6. Some developed the ability to attach to cells expressing heparan sulfate (HS) proteoglycan, while others appear to have developed affinity for a still unknown third receptor. Two classes of SIR mutants were selected that were highly or moderately resistant to neutralization by ssαvβ6. Highly resistant mutants displayed a G145D substitution (RGD to RDD), while moderately resistant viruses exhibited a L150P/R substitution at the conserved RGD + 4 position. VP1 G-H loop homology models for the A-type SIR mutants illustrated potential structural changes within the integrin-binding motif by these 2 groups of mutations. Treatment of O1 Campos with ssαvβ6 resulted in 3 SIR mutants with a positively charged VP3 mutation allowing for HS binding.

Conclusions

These findings illustrate how FMDV particles rapidly gain resistance to soluble receptor prophylactic measures in vitro. Two different serotypes developed distinct capsid mutations to circumvent the presence of sub-neutralizing levels of the soluble cognate receptor, all of which resulted in a modified receptor tropism that expanded the cell types susceptible to FMDV. The identification of some of these adaptive mutations in known FMDV isolates suggests these findings have implications beyond the cell culture system explored in these studies.

Keywords:
Soluble receptor; αv-integrin heterodimers; Foot-and-mouth disease virus (FMDV)

Introduction

Foot-and-mouth disease virus (FMDV) is responsible for the most economically important viral disease of cattle and other cloven-hoofed animals [1-5]. FMDV, the prototypic member of the Aphthovirus genus of Picornaviridae, utilizes in vitro four integrin heterodimers (αvβ1, αvβ3, αvβ6, and αvβ8) for attachment to host cells and entry via clathrin-coated pits (CCPs) [6-14]. A prominent surface-exposed loop connecting the βG-βH strands (G-H loop) of the VP1 capsid protein contains a highly conserved Arg-Gly-Asp (RGD) motif, a recognition sequence for the αv-integrin family of cell surface receptors [6,15-17]. Limited trypsin proteolysis removes the G-H loop, producing FMDV particles considerably less infectious relative to untreated virions, highlighting the importance of this region for productive infection [18-20]. Following integrin binding, CCPs internalize virus into acidic endosomes where uncoating occurs. FMDV field isolates continually passaged in cell culture adapt to utilize heparan sulfate (HS) as an alternative receptor, and exhibit attenuated pathogenicity [21-24].

Previously, soluble αvβ3 and αvβ6 lacking the transmembrane and cytoplasmic tail domains were shown to still function as FMDV receptors [25]. Pre-treatment of serotype A and O FMDV particles with soluble secreted bovine αvβ3 and αvβ6 prior to application on permissive cell lines was investigated as an antiviral therapy. Interestingly, only soluble αvβ6 limited FMDV attachment to host cells by competing for receptor binding sites on virus particles. Soluble αvβ3 exhibited a low affinity interaction with the virus particles and failed to attach to FMDV in the same manner as αvβ6 with no significant effect on infectivity. It remains to be determined whether binding to blocking molecules such as soluble receptor, will impact FMDV interaction with the cell-membrane receptor or affect viral growth.

Here, we conducted in vitro experiments to evaluate the selective pressure exerted by soluble receptor protein on FMDV attachment and examined the evolution of virus-host cell interactions. Studies conducted with poliovirus and its cognate receptor [26,27] showed that surface and internal capsid residues regulate attachment to the receptor and conformational change of the virus. Here, sub-neutralizing levels of soluble secreted bovine αvβ6 (ssαvβ6) were used to develop soluble receptor resistant mutants of FMDV A24 Cruzeiro. Of the 4 αv-integrins used by FMDV for host cell attachment, the β6 heterodimer was selected on the basis that ssαvβ6 most substantially impeded FMDV infection [25]. Additionally, the β6 heterodimer was shown to be most responsible for the tissue tropism of FMDV in cattle [28]. Following 3 successive passages of FMDV (serotype A and serotype O) pre-treated and co-incubated with ssαvβ6 on the LFBK cell line, which is permissive to infection by all 7 serotypes of FMDV (Figure 1, Table 1) [29], virus was isolated that persisted despite the presence of soluble integrin (SI). The A-type isolates exhibited mutations in the normally conserved RGD motif or just outside of it within the G-H loop of VP1, while the O-type mutants displayed changes in VP3 and residues proximal to the VP1 RGD motif. SI resistant (SIR) FMDV mutants were further characterized for altered receptor tropism, relative sensitivity to neutralization by SI, as well as sequence and structural alterations in the G-H loop.

thumbnailFigure 1. Integrin expression profile. BHK-21, CHO 677, and LFBK cell lysates were examined by Western blot probing with: anti-β3 integrin (ITGβ3), anti-β6 integrin (ITGβ6), and anti-RHA. Equivalent loading between lanes was confirmed by probing with anti-tubulin-α. Molecular weight ladder bands are indicated.

Table 1. Receptor repertoire of tested cell lines

Results

Selection of FMDV serotype A SIR mutants

To examine the adaptability of serotype A FMDV (represented by A24 Cruzeiro) to the presence of soluble receptor during infection, we employed ssαvβ6, which is preferentially exploited by serotype A FMDV for host cell attachment [7,25]. As previously described, ectodomains of αv and β6 integrin subunits were secreted from stably transfected cells, which were properly folded and capable of heterodimerization (data not shown) [25]. The bovine kidney LFBK cell line was selected for these studies on the basis that it is susceptible to infection by all 7 FMDV serotypes, similar to primary bovine kidney cell culture and [29]. Western blot analysis confirmed that LFBK cells express both β3 and β6 integrins (Figure 1, Table 1). As expected, CHO 677 cells [30,38] did not express β3 and β6 integrins [21,30-33,39-41]. While BHK-21 cells expressed β3 integrin, we were unable to detect the presence of β6 integrin. As an additional control, RNA Helicase A (RHA), known to be expressed in all 3 cell lines, was also detected. By extension, these findings allowed for the potential that both αvβ3 and αvβ6 could be found on the surface of LFBK cells, which is consistent with repeated experiments showing the susceptibility of this cell line to non-HS-adapted field isolates of FMDV (data not shown).

Wild-type (WT) FMDV A24 Cruzeiro was pre-incubated with 10 μg/mL ssαvβ6 (sub-neutralizing concentration for A24 Cruzeiro, Additional file 1: Figure S1) at 37°C for 1 hour prior to application of the coated virus on LFBK cells. As depicted in Figure 2A, LFBK cells were infected with ssαvβ6 coated WT FMDV A24 Cruzeiro at a MOI of 1 at 37°C for 24 hours (P1). Thirty-five plaques were isolated and used for a second round (P2) of infection with ssαvβ6. Only 17 of the 35 infections demonstrated cytopathic effects (CPE) at 24 hpi. Isolates from 17 P2 infections were individually used for a third selection (P3) with ssαvβ6. This resulted in only 4 productive infections derived from A24 Cruzeiro numbered: 15, 23, 42, and 45. The 4 soluble integrin resistant (SIR) serotype A (A-type) isolates (designated A-SIR #15, A-SIR #23, A-SIR #42, and A-SIR #45) were subject to a final selection with ssαvβ6, where by 24 hpi A-type SIR isolates 15, 23, and 45 produced 100% CPE and isolate 42 produced 50% CPE.

Additional file 1. Figure S1. Soluble integrin neutralization assay. Titration experiment performed where A24 Cruzeiro was pre-incubated with gradually increasing amounts of ssαvβ6 to determine a suitable sub-neutralizing soluble receptor concentration.

Format: JPEG Size: 273KB Download fileOpen Data

thumbnailFigure 2. A-SIR mutant generation. A. Schematic of A-SIR mutant production. B. Comparison of the plaque morphology and titers achieved of A- SIRs relative to A24 Cruzeiro after pre-treatment and co-incubation with ssαvβ6 on LFBK (top panel) and CHO K1 (bottom panel) cells for 24 h. SIR #42 was the only virus that amplified on CHO 677 cells (right box). Titers represent PFU/mL. C. WT and A-SIR viruses were co-incubated with increasing concentrations of ssαvβ6 on LFBK monolayers for 24 h, and the calculated titers were subsequently plotted.

After multiple passages in cell culture, FMDV has been shown to gain the ability to attach to host cells via HS [14,21-24,43]. To determine if the A-type SIR mutants adapted to use HS for entry, replication of these viruses on LFBK and Chinese hamster ovary (CHO) K1 cells was compared. In contrast to LFBK cells, CHO K1 cells express HS, but not αvβ1, αvβ3 and αvβ6 (Table 1) [24,30-35]. Of note, CHO K1 cells express 2 RGD-binding integrins (α5β1 and αvβ5), but neither function as FMDV receptors [7,10,30]. WT and A-SIR viruses successfully infected LFBK cells (Figure 2B, top panel). However, WT and A-SIRs #15 and #23 were unable to infect CHO K1 cells. In contrast, A-SIRs #42 and #45 productively infected CHO K1 cells (Figure 2B, bottom panel). Thus, we suggest that A-SIRs #42 and #45 circumvented ssαvβ6 neutralization by expanding their receptor preference to include HS, as previously observed under other conditions with different FMDV serotypes [23,24].

The A-type SIR mutants diverged with respect to their plaque morphologies on different cell lines. WT and A-SIR mutants maintained relatively large plaque sizes on LFBK cells (Figure 2B, top panel). On CHO K1 monolayers, A-SIRs #42 and #45 showed reduced plaque size relative to LFBK cells (Figure 2B, lower panel). Comparative viral growth on LFBK and CHO K1 cells suggests some A-SIRs might utilize HS. To examine this further, the growth analysis was expanded to include the CHO 677 cell line (Figure 1, Table 1) [39,40,44]. In addition, the IBRS2 cell line with a unique receptor profile where FMDV infection is initiated via αvβ8[9,16,42], was also examined (Table 1). IBRS2 cells were permissive to infection by WT and A-SIR viruses, growing to titers comparable to LFBK cells (Table 2). Interestingly, A-SIR #42 productively infected CHO 677 cells (Figure 2B, Table 2). SIR #42 grew to roughly equivalent titers on CHO 677 and CHO K1 cells (Figure 2B, Table 2). Viral growth on CHO 677 cells suggested this A-SIR mutant adapted to utilize an as yet unidentified and uncharacterized third FMDV receptor [21,41]. It was inferred that growth of A-SIR #45 on CHO K1 cells but not CHO 677 cells was indicative that this virus exploited HS. Different growth patterns for each A-SIR mutant on different cell lines also suggested these viruses are genetically distinct. These findings illustrated the rapid adaptability (after only 3 passages) of serotype A FMDV to overcome interference with host cell attachment.

Table 2. Growth comparison of A24 Cruzeiro WT and A-type SIRs on 6 cell lines

A-SIR mutants exhibit reduced sensitivity to SI neutralization

Next, the relative sensitivities of A-SIR mutants to ssαvβ6 neutralization were examined relative to their WT counterpart. Each virus was pre-incubated with ssαvβ6 at gradually increasing concentrations (5, 10, 20, 30, and 40 μg/mL), applied to LFBK monolayers, and evaluated for reductions in virus titer. As shown in Figure 2C, the four A-SIR mutants could be divided into 2 classes with respect to sensitivity to neutralization by ssαvβ6: a highly resistant (#15 and #23, Class I) and a moderately resistant class (#42 and #45, Class II). A-SIRs #15 and #23 grew to titers 200–1000 fold higher than WT with increasing ssαvβ6, while mutants #42 and #45 exhibited titers 20–100 fold higher than WT (Figure 2C). Cumulatively, these findings reinforced the supposition that pre- and co-incubation of ssαvβ6 acts as a selective pressure forcing FMDV particles to quickly select for resistance to the treatment.

A-SIR mutants continue to utilize αvβ6

Since the A-SIR mutants exhibited reduced sensitivity to ssαvβ6 neutralization, we investigated whether they exhibit an altered integrin preference: shifting from αvβ6 to another integrin or a non-integrin receptor. The capability of A-SIRs to infect cells expressing distinct integrins was tested using a previously established transient transfection-infection assay [45]. COS-1 cells do not support FMDV infection and lack integrins used by FMDV (Table 1) [7]. These cells were co-transfected with plasmids encoding the full-length αv-integrin subunit and 1 of 4 different full-length β subunits (β1, β3, β5, or β6). Expression was confirmed by immunocytochemical staining (Figure 3A). Of note, the antibody used to detect the αvβ1 only recognizes the β1 subunit; as such, positive staining may be reflective of other β1 containing integrin heterodimers.

thumbnailFigure 3. A-SIR mutants maintain αvβ6 affinity. A. Expression of αv and β subunits (β1, β3, β5, or β6) examined by immuno-histochemical staining using indicated antibodies. Untransfected cells probed as a negative control. B. RIP analysis of transfected cells infected with: A24 Cruzeiro and A-SIRs in the presence of 35S-methionine. NT, not transfected. PC, positive control: virus-infected LFBK cells.

WT virus and A-SIR mutants were incubated on the cells transiently expressing integrin with 35S-methionine. After 24 hours, levels of viral protein synthesis were evaluated by radioimmunoprecipitation (RIP) (Figure 3B). Based on the sets where FMDV proteins (3D, VP0, VP1-3) were detected, it could be inferred as to which integrin heterodimers was/were used by WT and A-SIR viruses to gain entry to COS-1 cells for replication. Consistent with previous reports, viral protein synthesis was detected for A24 Cruzeiro WT in cells expressing αvβ1, αvβ3 and αvβ6 (Figure 3B) [7,25]. A-SIRs #15 and #23 were only amplified on αvβ6 expressing cells. A-SIRs #42 and #45 infected cells displaying αvβ1 and αvβ6. However, the signal for virus proteins was noticeably lower for A-SIR #42 and #45 relative to WT, though we cannot exclude the possibility that this was partially due to differences in transfection efficiencies. Besides WT, A-SIR #45 was the only other virus able to infect via αvβ3. Interestingly, although resistant to neutralization by ssαvβ6, all 4 A-SIR viruses replicated on αvβ6 expressing COS-1 cells. Thus, it was inferred that all 4 A-SIR mutants maintained sufficient affinity for αvβ6 to continue to infect cells via this receptor.

To reinforce the supposition that the A-SIR viruses retained the ability to bind αvβ6, CHO 677 cells, which could not permit FMDV infection except for A-SIR #42, were transiently transfected with αvβ6 as was done for COS-1 cells (data not shown). The expression of αvβ6 restored infectivity of WT and A-SIR viruses, with titers within 0.5 to 1 log less than on LFBK cells (Table 2), with A-SIR #45 attaining a titer 1 log higher than both class I SIRs. Notably, A-SIR #42 achieved titers 2 logs higher than on untransfected CHO 677 cells, suggesting αvβ6 is the preferred surface receptor for this virus.

Amino acid substitutions detected in A-SIR mutants

To further distinguish A-SIR viruses from their parental counterpart, A-SIR mutants were examined for alterations in their nucleotide and amino acid sequences relative to WT (Accession #AY593768). No amino acid substitutions were detected in VP4, VP2, or VP3, with a single silent mutation detected in VP3. Interestingly, the 2 A-type SIR classes exhibited 2 corresponding types of mutations in VP1 summarized in Table 3 and Figure 4. Class I A-SIRs that were highly resistant to ssαvβ6 (#15 and #23) displayed a G145D amino acid substitution in the RGD motif considered essential for integrin interaction. The V154A substitution distinguished A-SIR #23 from #15. Class II A-type SIRs moderately resistant to ssαvβ6 (#42 and #45) exhibited substitutions at the RGD + 4 position with L150P for #42 and L150R for #45. Moreover, A-SIR #42 displayed 2 additional amino acid alterations upstream of the RGD motif: E95K and S96L. Previous reports have described the helical segment immediately C-terminal to the RGD motif as contributing to the interaction between FMDV and its cognate integrin receptor, specifically, amino acid positions RGD + 1 and RGD + 4. The RGD + 1 and RGD + 4 side chains face out like those of the RGD motif and are frequently occupied by leucine residues [8,14,46-49]. While proline substitution at the RGD + 4 position was previously detected in the A5 Westerwald FRG/58 field isolate ( [50]b; [51]) and serially passaged populations of a serotype C FMDV strain [21], the arginine substitution at this position appears unprecedented. Cumulatively, the P1 sequences support the findings that 2 distinct classes of SIR mutants were derived from A24 Cruzeiro: where each class exhibited distinct forms of amino acid substitutions localized to the VP1 G-H loop.

Table 3. Sequence comparison of the P1 region of A24 Cruzeiro and A-SIRs

thumbnailFigure 4. Amino acid substitutions within the P1 region of A-SIR mutants. Schematic of the FMDV genome summarizing the amino acid substitutions identified in the P1 region of A-SIR mutants after viral RNA from A24 Cruzeiro and A-SIRs was sequenced for amino acid substitutions in P1.

Structural predictions of A-SIR mutant modifications

After defining the amino acid changes within VP1 in the A-SIR mutants (Figure 4), we explored how those changes might affect the overall structure of the receptor-binding site in the G-H loop. The VP1 crystal structure has been solved for FMDV O1/BFS 1860/UK/67 (Accession 1FOD) [52]. Using the coordinates of 1FOD as a template, homology structures were generated of WT A24 Cruzeiro VP1 as well as those of the 4 A-SIR mutants using the Geno3D algorithm [53]. For each virus, 10 different “best fit” homology models were generated for VP1. Representative images of the G-H loop region were given particular scrutiny (Figure 5).

thumbnailFigure 5. Structural prediction of the effect of the A-SIR amino acid substitutions on the G-H loop. Depicted are 2 angles (A and B) of models of the VP1 G-H loop of A24 Cruzeiro and representative class I and class II A-SIRs. RGD motif is indicated, and residues are colored: arginine (R), blue; glycine (G), green; aspartic acid (D), red. RGD + 4 position (L/P + 4) is violet. Black arrows indicate altered directionality of the amino acid side chains in A-SIR RGD/RDD sites.

The RGD to RDD substitution detected in class I A-SIR mutants #15 and #23 placed a bulky negatively charged residue into the center of the integrin binding site, which can be seen projecting outward in the homology structures generated. The introduction of D145 “spread out” the adjacent side chains within the RGD motif, increasing the distance between the R144 and D146 side chains relative to WT (Figure 5). In all 10 of the predicted tertiary structures, the amino acid alteration failed to effect any significant change in the backbone structure of this region of VP1.

The previously undetected L150R substitution at the RGD + 4 position of class II A-SIR #45 replaces a linear non-polar amino acid side chain with a positively charged residue. Interestingly, Geno3D failed to predict a consensus structure for the A-SIR #45 G-H loop. Class II A-SIR mutant #42 exhibited a L150P substitution at RGD + 4, which was previously identified in FMDV A5 Westerwald FRG/58 [50,51]. The homology model of the A-SIR #42 G-H loop revealed the proline residue introducing a kink that “compressed” the RGD motif with the three side chains in much closer proximity than WT (Figure 5). This structural prediction was essentially the opposite of what was produced for the class I A-SIR mutants.

In addition to L150P, A-SIR #42 also displayed 2 substitutions upstream of the RGD: E95K and S96L, which are proximal to the VP1-VP3 interface. Using Geno3D, ribbon diagrams were generated of capsid protomers from WT and A-SIRs to determine if the protein interface was disrupted (Additional file 2: Figure S2). A short helical domain observed at the VP1-VP3 interface in the WT sequence was notably absent with the E95K/S96L substitution, replaced with a loop structure. With L150P previously detected in A5 Westerwald, E95K/S96L may be more significant to the adaptation of A_SIR #42. We concluded that the mutations elucidated in the A-SIR mutants produce hypothetical structural alterations likely to affect cellular recognition.

Additional file 2. Figure S2. Structural prediction of the effect of the A-SIR amino acid substitutions on the capsid protomer. Depicted are 3 ribbon models of the FMDV capsid protomer (excluding VP4) of A24 Cruzeiro (A) and class I (B) and class II (C) A-SIRs. Black arrows indicate the RGD motif and the RGD + 4 position. Blue arrows indicate the VP1-VP3 interface. VP1 is yellow, VP2 is blue, and VP3 is red.

Format: JPEG Size: 1.5MB Download fileOpen Data

O1 Campos derived SIR mutants circumvent ssαvβ6 by a different mechanism

A-SIR mutants derived from A24 Cruzeiro overcame the selective pressure introduced by ssαvβ6 by compensatory mutations targeted to the RGD motif or the RGD + 4 position within the VP1 G-H loop. In an effort to determine if a similar strategy would be exploited by a different FMDV serotype, the experiment was repeated whereby O1 Campos was pre-treated and passaged three times in the continued presence of 10 μg/mL ssαvβ6 (also a sub-neutralizing concentration for O1 Campos, data not shown). Three O-type SIR viruses were recovered designated O-SIR #1, O-SIR #9, and O-SIR #46 (Figure 6A). All three O-SIRs produced similar small plaque forming units on LFBK cells relative to their WT progenitor (Figure 6B, top panel). Unlike the WT virus, the O-SIRs productively infected CHO K1 cells (Figure 6B, bottom panel), achieving titers approximately 1 log lower than on LFBK cells (Table 4). This suggested that the O-SIRs adapted to the presence of ssαvβ6 by selecting an affinity for HS, which represents a well-characterized strategy employed by serotype O FMDV [22,23,54]. Each O-SIR mutant produced distinct plaque morphologies on CHO K1 cells; with large plaques for O-SIR #1, medium-sized plaques for O-SIR #9, and small pinprick plaques for O-SIR #46 (Figure 6B, bottom panel). Interestingly, like the A-type SIR mutant #42, O-SIR #9 could replicate, albeit to a limited titer, on CHO 677 cells (Figure 6B, right panel and Table 4). When CHO 677 cells transiently expressing αvβ6 were substituted in this assay, infectivity was restored for all O-SIR mutants and O1 Campos WT, with titers equivalent to or exceeding those on LFBK cells (Table 4). This particular finding was consistent with what was observed for the A-SIR viruses, where affinity for αvβ6 was maintained. Additionally, both O1 Campos and the O-SIR mutants demonstrated titers 1–2 logs higher on IBRS2 cells relative to LFBK cells (Table 4), which suggested that these viruses infect via αvβ8 with greater efficiency.

thumbnailFigure 6. O1 Campos derived SIR mutants exhibit distinctive alterations. A. Schematic of O1 Campos derived O-SIR mutant production. B. Comparison of the growth characteristics of O-SIRs relative to O1 Campos after ssαvβ6 co-incubation on LFBK and CHO K1 cells. O-SIR #9 was the only virus that amplified on CHO 677 cells. Titers represent PFU/mL. C. WT and O-SIR viruses were co-incubated with ssαvβ6 on LFBK monolayers for 24 h, and the calculated titers were subsequently plotted. D. RIP analysis of untransfected LFBK and COS-1 cells infected with: O1 Campos and O-SIRs in the presence of 35S-methionine. NT, not transfected (COS-1). PC, positive control (LFBK). E. FMDV genome depicting amino acid substitutions identified in the P1 region of O-SIR mutants.

Table 4. Growth comparison of O1 Campos WT and O-type SIRs on 6 cell lines

Further analysis revealed that all three O-SIRs were uniformly 2 logs more resistant to neutralization by ssαvβ6 up to 20 μg of ssαvβ6 (Figure 6C). However, while this resistance was maintained by O-SIR #1 and O-SIR #9 above 20 μg ssαvβ6, O-SIR #46 was inhibited by ssαvβ6 at concentrations above 20 μg. Initial examinations of the reliance of the O-SIRs on different integrin heterodimers revealed the presence of FMDV proteins in untransfected COS-1 cells infected with the O-SIR mutants, similar to the pattern observed for O-SIR infected LFBK cells (Figure 6D). No increase in viral protein synthesis was observed for cells transiently expressing integrins (data not shown). Like CHO K1 cells, COS-1 cells express HS, thus it was inferred that the O-SIR mutants had circumvented ssαvβ6 neutralization by adapting to utilize HS for host cell attachment.

Given the disparities in plaque morphology and sensitivity to soluble integrin neutralization, it was expected that the O-type SIR mutants would be genetically distinct. In contrast to A-SIRs, compensatory mutations were not confined to VP1, but were also identified within VP3 (Figure 6E). The mutations detected in the O-SIRs were consistent with those previously found in HS-adapted serotype O FMDV passaged multiple times in cell culture with a signature H56R substitution in VP3 [22,23,54]. An additional D60A substitution in VP3 and an E113V substitution in the VP1 G-H loop were found in all O-SIR viruses. O-SIRs were distinguished from each other by 2 unique amino acid substitutions: R155W in the VP1 G-H loop of O-SIR #1 and Q28L in VP1 and V90A in VP2 of O-SIR #9. Notably, the conserved RGD motif and RGD + 4 amino acid positions were unchanged.

Cumulatively, the development and characterization of the A-SIR and O-SIR FMDV mutants and the evolution of the virus-host interaction under the selective pressure of soluble integrin treatment was determined in the present study.

Discussion

Distinct lineages of RNA viruses are frequently referred to as “quasi-species” due to their inherent mutability [47,55]. Their rapid adaptability stems from the lack of “proofreading” function in the RNA-dependent RNA polymerases responsible for amplification of RNA viral genomes. The poliovirus RNA polymerase delivers approximately 1 error in 2200 bases, which is significant for a virus genome of approximately 7500 nucleotides [56]. Constant variation with each duplicated RNA viral population represents a stumbling block in the development of anti-viral therapies. A previous study explored using soluble receptor treatments to impair FMDV infection [25,49]. Here, we investigated the effect of sub-neutralizing levels of soluble secreted αvβ6 (ssαvβ6) on FMDV replication in cells and documented the rapid emergence of resistant FMDV populations, how they circumvented the selective pressure of ssαvβ6, and the strategies deployed as they adapted.

Previous studies have investigated the effect of multiple passaging in cell culture on FMDV acquisition of alternative receptors, attenuated phenotypes, and for the dispensability of the RGD motif [21,49,57]. For instance, following 100 passages of a serotype C FMDV (C-S8c1) in cell culture, the virus was able to enter cells by an integrin-independent manner and multiple mutations were identified in the variant genomes [21]. For serotype A12 virus, it has been shown that mutations obtained during adaptation of field (bovine) isolates to cell culture localize downstream of the RGD and those mutations appear to alter the affinity for the integrin receptor [49].

Here, four SI resistant (SIR) FMD viruses derived from A24 Cruzeiro and three derived from O1 Campos were rapidly selected after only 3 rounds of cell culture selection in the continued presence of ssαvβ6. The A-SIR mutants could be separated into 2 classes that were either highly or moderately resistant to neutralization by ssαvβ6. Highly resistant A-SIRs (Class I) did not select HS as a secondary receptor and maintained αvβ6 affinity. These variants displayed a G145D substitution in the highly conserved VP1 RGD motif. The moderately resistant A-SIRs (Class II) also retained αvβ6 affinity and appeared to either utilize HS or an as yet unidentified and uncharacterized third FMDV receptor. Moreover, similar to A24 Cruzeiro, all 4 A-SIR mutants were amplified on IBRS2 cells, indicating that the A-SIRs have maintained the ability to infect and replicate on cells expressing an abundance of αvβ8, which can also function as a FMDV receptor [9,16,42].

Class I A-SIR Mutants

A-SIR mutants appear to have circumvented ssαvβ6 treatment by 2 different routes. Substitution of an aspartic acid (G145D) in the RGD motif (Figure 4) rendered A-SIR #15 and 23 (Class I) highly resistant to ssαvβ6 (Figure 2C) while paradoxically maintaining use of αvβ6 for infection (Figure 3B). Notably, class I A-SIRs did not adapt to utilize HS. Interestingly, this RDD mutation in the cell receptor binding site has been detected in a field strain of Asia1 virus (Asia1/JS/CHA/05) after just 2 passages, one in vivo and one in vitro[57]. RDD Asia1 variants showed no change in their ability to replicate in established cell lines, nor did it alter clinical onset of disease in animals tested [57]. While the environmental pressure that selected for RDD Asia1 variants is unknown, it suggests that this mutation might be a natural adaptation mechanism that could manifest across different FMDV serotypes. This hypothesis is supported by the observation that natural outbreaks of serotype A FMDV featuring the RDD amino acid substitution have occurred in Argentina on two occasions: A25-Arg/59 (GenBank #AY593769) and A25-Arg/61 (GenBank #AY593789).

The likely reason for the selection of a modified RGD was also investigated using homology models of the VP1 G-H loop structure and position of the RDD side chains (Figure 5). The data showed an additional negative charge provided by G145D widened the gap between the side chains of R144 and D146. Potentially, the widening of the RDD side chains or the introduction of an additional negatively charged side chain might diminish the affinity of the motif for the integrin by sterically complicating the binding of ssαvβ6, which is not anchored to a membrane, to the virus particle during pre-treatment in solution. Correspondingly, by reducing the affinity but not ablating the interaction with αvβ6 (Figure 3B, Table 2), unoccupied RDD sites on the virus particle after pre-treatment and subsequent co-incubation with ssαvβ6 likely allow infection of host cells via αvβ6.

Class II A-SIR Mutants

In contrast, moderately resistant Class II A-SIRs left the RGD intact, but substituted a key amino acid at the RGD + 4 position [8,14,46-48], with the conserved leucine replaced with proline for A-SIR #42 and arginine for A-SIR #45. L150P was previously identified in FMDV A5 Westerwald FRG/58 [50,51] as well as a multiply passaged serotype C FMDV [21,58]. However, L150R appears unprecedented. Interestingly, while both viruses replicated in CHO K1 cells, only A-SIR #42 infected CHO 677 cells. However, both class II A-SIRs exhibited preference for αvβ6 over alternative surface molecules (Figure 2, Table 2). Given L150P was previously detected in the WT field strain A5 Westerwald [51], it will be interesting to explore in the future whether this amino acid alteration was solely responsible for shifting receptor tropism to allow infection of cells devoid of FMDV integrin receptors and HS [21,30,38,41]. However, two additional mutations detected in VP1, E95K and S96L, might also contribute or be exclusively responsible for the A-SIR #42 phenotype.

Homology modeling was also employed to illustrate how Class II amino acid substitutions affected both the G-H loop (Figure 5) and the capsid protomer (Additional file 2: Figure S2). In contrast to Class I A-SIRs, L150P appears to compress the side chains projecting from the RGD motif, where R144 and D146 are in closer proximity than in A24 Cruzeiro or Class I A-SIRs (Figure 5). The unique E95K/S96L substitutions localized to the VP1-VP3 interface, potentially altering capsid protomer stability (Additional file 2: Figure S2). Modeling algorithms failed to generate a consensus structure for the G-H loop of A-SIR #45, where multiple potential side chain angles for L150R altered the shape and presentation of the RGD motif (data not shown).

O-SIR mutants

When the approach used to generate the A-SIRs was applied to O1 Campos, this resulted in three distinctive O-SIR mutants that bind to HS and that carried a signature H56R mutation. This particular mutation has been observed in attenuated HS-adapted FMDVs [22,23,54]. Similar to their A-type counterparts, the O-SIRs also could be amplified on IBRS2 cells suggesting that the selective pressure of co-incubation with ssαvβ6 did not abrogate the affinity for αvβ8. However, unlike A24 Cruzeiro and the A-SIRs, O1 Campos and the O-type SIR mutants amplified 2–3 logs more in IBRS2 cells relative to LFBK cells, thus it could be inferred that serotype O FMDV may have a preference for αvβ8 as a receptor. As such it would be intriguing to explore the effects of successive passages of O1 Campos in the presence of ssαvβ8 in the future. Lastly, it is interesting to note that the mutations accumulated by the O-SIRs were not in the VP1 RGD motif, but rather peripheral to it and at locations in VP3, separate from the primary site of attachment to the host cell.

Conclusions

Together the results of this study have shed light on the plasticity of FMDV serotype A and O interactions with its primary cognate receptor: αvβ6. Amino acid substitutions detected in SIR mutants were rapidly selected to overcome soluble receptor neutralization. Thus, the tolerance of the VP1 G-H loop to amino acid substitutions plays an essential role in cell receptor adaptability of FMDV. Interestingly, mutations identified in the current study have been also identified in FMDV field isolates causing outbreaks suggesting that similar selective pressures may exist in the natural host environment. The mode and relative speed with which FMDV was able to adapt to a selective pressure, represented here by ssαvβ6, highlights both the evolutionary advantage of highly mutable RNA viruses and the challenges of designing effective antiviral therapies against these pathogens.

Materials and methods

Materials

Fugene-6 was purchased from Roche (Nutley, NJ). Mouse monoclonal anti-β3 integrin (ITGβ3) was purchased from Abcam (Cambridge, MA). Rabbit polyclonal anti-β6 integrin (ITGβ6) was purchased from Sigma (St. Louis, MO). Mouse monoclonal anti-β1 integrin (6S6), anti-αvβ3 integrin (LM609), anti-αvβ5 integrin (15 F11), and anti-β6 integrin (CSβ6) was purchased from Millipore (Billerica, MA). Rabbit polyclonal anti-RHA was purchased from Bethyl Laboratories (Montgomery, TX).

Cells, viruses, and plasmids

IBRS2, COS-1, and 293a cell lines purchased from American Tissue Collection Company (ATCC; Manassas, VA) were cultured in Dulbecco’s minimal eagle medium (DMEM) with 10% fetal bovine serum (FBS) at 37°C with 5% CO2. LFBK cell line was previously described [29], and cultured in DMEM with 10% FBS at 37°C with 5% CO2. CHO K1 and 677 cell lines were acquired from Dr. Jeffrey Esko [39] and cultured in Ham’s MEM (Gibco) with 10% FBS at 37°C with 5% CO2. FMDV A24 Cruzeiro field strain was derived from pA24-Cru [59]. FMDV O1 Campos field strain was previously described [24].

SI production

Expression and purification of ssαvβ3 and ssαvβ6 was previously described [25]. Plasmids encoding ectodomains of integrin subunits (αv, β3, and β6) were transfected using Fugene-6 (Roche) per manufacturer’s instructions. Stable expression was selected by incubating with G418 (αv gene sub-cloned into pcDNA3.1-G418) and zeomycin (β3 and β6 gene sub-cloned into pcDNA3.1-Zeo). Supernatants were collected and concentrated 10-fold using Centricon Plus-70 filter devices (Millipore, Billerica, MA). Subsequent protein concentration measured between 125–250 μg/mL.

Radio-immunoprecipitation (RIP)

Virus-infected cells grown overnight in the presence of 35S-methionine were lysed with 1% Triton X100. Aliquots of each sample were precipitated with 20% trichloroacetic acid (TCA) to determine the counts per minute (cpm). Lysates were mixed with Protein A/G agarose beads, tumbled 15 minutes, centrifuged at 1500 rpm 10 minutes, and the supernatants collected. Recovered supernatant was tumbled with indicated antibodies (6S6, LM609, 15 F11, and CSβ6) 1 hour at 4°C. The mixture was tumbled overnight at 4°C with fresh Protein A/G agarose. Afterwards, the agarose was washed 3 times with NET/NP40 buffer (NaCl, EDTA, Tris, Nonidet-P40). Finally, the agarose was boiled in sample buffer without β-mercaptoethanol, pelleted, the supernatants separated by SDS-PAGE, and the gel examined by autoradiography.

Transient transfection-infection assay

Assay was conducted as previously described [45]. Two sets of COS-1 or CHO 677 cells were transfected with 2 plasmids: one encoding full-length αv-integrin subunit and the other encoding 1 of 4 different full-length β subunits (β1, β3, β5, or β6). The first sets were examined by immuno-histochemical staining to confirm expression, using antibodies: 6S6 (αvβ1), LM609 (αvβ3), 15 F11 (αvβ5), and CSβ6 (αvβ6). 6S6 binds the β1 subunit and COS-1 cells express α5β1, which is not a cellular receptor for FMDV [11,12,21]. The other sets were infected with WT and SIR viruses at a MOI of 1 in 35S-methionine containing media. Subsequently, virus-infected cell lysates were examined by RIP for virus-specific bands: 3D, VP0, and VP1-3.

Virus titer assay

One hour post-adsorption, the inoculum was removed, and cells washed in a mild acid solution followed by virus growth media (VGM, DMEM containing L-glutamine). VGM was then added and cells incubated 24 hours at 37°C. Afterwards, virus-infected cells were harvested and titers determined by plaque assay as previously described [60]. Plates were fixed, stained with crystal violet (0.3% in Histochoice; Amresco, Solon, OH), and plaques counted. Values calculated for number of plaque-forming units (PFUs) per milliliter (mL) were plotted using Microsoft Excel (Microsoft Corporation, Redmond, WA). Assays were performed in triplicate.

Western blot

Protein samples were separated by Nu-PAGE® pre-cast gel system (Invitrogen), and electro-blotted onto nitrocellulose (Sigma). After blocking with 5% milk, proteins were detected with indicated primary integrin antibodies (anti-β3, Abcam and anti-β6, Sigma) followed by HRP-conjugated goat-anti-mouse or goat-anti-rabbit antibodies (Bethyl Laboratories), respectively. Cellular tubulin, employed as a loading control, was detected with HRP-conjugated anti-tubulin-α (Abcam, Cambridge, MA). HRP was reacted with WestDura SuperSignal chemiluminescent reagent (Pierce) and visualized on X-ray film (X-Omat; Kodak, N.Y., USA).

Sequencing of the FMDV P1 Region

The P1 region in twenty FMDV isolates were sequenced from PCR product with sequencing primers providing at least 3X coverage across 3,000 base pairs. PCR products were purified with QIAQuick spin columns (Qiagen) in accordance with the manufacturer's instructions. Sequencing reaction mixtures (10 μl) contained 2.5 μM primer, 20 ng of PCR product, and 0.75 μl of Big Dye (Applied Biosystems) in molecular biology-grade water. The sequence cycling conditions were 30 s of pre-incubation at 85°C; 25 cycles of 10 s at 96°C, 5 s at 50°C, and 4 min at 60°C; and a 10-min 60°C final extension. The sequencing reaction mixtures were purified with Agencourt’s CleanSEQ system in accordance with the manufacturer's instructions (Beckman Coulter).

Structural analysis

Amino acid sequences of SIRs were used to construct homology models of the G-H loop and capsid protomers using the Geno3D algorithm [53]. Ten most likely structures were generated using a solved structure as a template. Two X-ray crystal structures for the major immunogenic site of FMDV designated 1FOD [52] and 1ZBE [61] in the Protein Data Bank (PDB) were selected as templates. Hypothetical structures were examined using DeepView [62,63], and a consensus structure for each sequence was selected.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

PL: evaluated the integrin expression on the tested cell lines, organized the sequencing data and performed the sequencing alignments, constructed the structural models, and drafted the manuscript. ML: produced the FMDV SIR mutants, evaluated SIR plaque morphologies and growth kinetics on indicated cell lines, and performed the radio-immunoprecipitation analysis. BB: co-conceived the study and participated in its design and implementation. ER: co-conceived the study and participated in its design, implementation, and coordination. All authors have read and approved the final version of the manuscript.

Acknowledgments

We wish to thank Bill Hurtle for his expertise sequencing the capsid region of FMDV SIR mutants. We also wish to thank Drs. Devendra Rai and Francois Maree for fruitful discussions regarding structural analyses of the SIR mutants. Dr. Paul Lawrence was sponsored by the Plum Island Animal Disease Research Participation Program administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the U.S. Department of Agriculture.

References

  1. Domingo E, Baranowski E, Escarmis C, Sobrino F: Foot-and-mouth disease virus.

    Comp Immunol Microbiol Infect Dis 2002, 25:297-308. PubMed Abstract | Publisher Full Text OpenURL

  2. Grubman MJ, Baxt B: Foot-and-mouth disease.

    Clin Microbiol Rev 2004, 17:465-493. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  3. Mason PW, Grubman MJ, Baxt B: Molecular basis of pathogenesis of FMDV.

    Virus Res 2003, 91:9-32. PubMed Abstract | Publisher Full Text OpenURL

  4. Saiz M, Nunez JI, Jimenez-Clavero MA, Baranowski E, Sobrino F: Foot-and-mouth disease virus: biology and prospects for disease control.

    Microbes Infect 2002, 4:1183-1192. PubMed Abstract | Publisher Full Text OpenURL

  5. Sobrino F, Saiz M, Jimenez-Clavero MA, Nunez JI, Rosas MF, Baranowski E, Ley V: Foot-and-mouth disease virus: a long known virus, but a current threat.

    Vet Res 2001, 32:1-30. PubMed Abstract | Publisher Full Text OpenURL

  6. Baxt B, Becker Y: The effect of peptides containing the arginine-glycine-aspartic acid sequence on the adsorption of foot-and-mouth disease virus to tissue culture cells.

    Virus Genes 1990, 4:73-83. PubMed Abstract | Publisher Full Text OpenURL

  7. Duque H, Baxt B: Foot-and-mouth disease virus receptors: comparison of bovine alpha(V) integrin utilization by type A and O viruses.

    J Virol 2003, 77:2500-2511. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  8. Jackson T, Blakemore W, Newman JW, Knowles NJ, Mould AP, Humphries MJ, King AM: Foot-and-mouth disease virus is a ligand for the high-affinity binding conformation of integrin alpha5beta1: influence of the leucine residue within the RGDL motif on selectivity of integrin binding.

    J Gen Virol 2000, 81:1383-1391. PubMed Abstract | Publisher Full Text OpenURL

  9. Jackson T, Clark S, Berryman S, Burman A, Cambier S, Mu D, Nishimura S, King AM: Integrin alphavbeta8 functions as a receptor for foot-and-mouth disease virus: role of the beta-chain cytodomain in integrin-mediated infection.

    J Virol 2004, 78:4533-4540. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  10. Jackson T, Mould AP, Sheppard D, King AM: Integrin alphavbeta1 is a receptor for foot-and-mouth disease virus.

    J Virol 2002, 76:935-941. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  11. Jackson T, Sheppard D, Denyer M, Blakemore W, King AM: The epithelial integrin alphavbeta6 is a receptor for foot-and-mouth disease virus.

    J Virol 2000, 74:4949-4956. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  12. Neff S, Sa-Carvalho D, Rieder E, Mason PW, Blystone SD, Brown EJ, Baxt B: Foot-and-mouth disease virus virulent for cattle utilizes the integrin alpha(v)beta3 as its receptor.

    J Virol 1998, 72:3587-3594. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  13. O'Donnell V, LaRocco M, Duque H, Baxt B: Analysis of foot-and-mouth disease virus internalization events in cultured cells.

    J Virol 2005, 79:8506-8518. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  14. Ruiz-Saenz J, Goez Y, Tabares W, Lopez-Herrera A: Cellular receptors for foot and mouth disease virus.

    Intervirology 2009, 52:201-212. PubMed Abstract | Publisher Full Text OpenURL

  15. Brown F, Benkirane N, Limal D, Halimi H, Newman JF, Van Regenmortel MH, Briand JP, Muller S: Delineation of a neutralizing subregion within the immunodominant epitope (GH loop) of foot-and-mouth disease virus VP1 which does not contain the RGD motif.

    Vaccine 1999, 18:50-56. PubMed Abstract | Publisher Full Text OpenURL

  16. Burman A, Clark S, Abrescia NG, Fry EE, Stuart DI, Jackson T: Specificity of the VP1 GH loop of Foot-and-Mouth Disease virus for alphav integrins.

    J Virol 2006, 80:9798-9810. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  17. Fox G, Parry NR, Barnett PV, McGinn B, Rowlands DJ, Brown F: The cell attachment site on foot-and-mouth disease virus includes the amino acid sequence RGD (arginine-glycine-aspartic acid).

    J Gen Virol 1989, 70(Pt 3):625-637. PubMed Abstract | Publisher Full Text OpenURL

  18. Robertson BH, Morgan DO, Moore DM: Location of neutralizing epitopes defined by monoclonal antibodies generated against the outer capsid polypeptide, VP1, of foot-and-mouth disease virus A12.

    Virus Res 1984, 1:489-500. PubMed Abstract | Publisher Full Text OpenURL

  19. Strohmaier K, Franze R, Adam KH: Location and characterization of the antigenic portion of the FMDV immunizing protein.

    J Gen Virol 1982, 59:295-306. PubMed Abstract | Publisher Full Text OpenURL

  20. Wild TF, Brown F: Nature of the inactivating action of trypsin on foot-and-mouth disease virus.

    J Gen Virol 1967, 1:247-250. PubMed Abstract | Publisher Full Text OpenURL

  21. Baranowski E, Ruiz-Jarabo CM, Sevilla N, Andreu D, Beck E, Domingo E: Cell recognition by foot-and-mouth disease virus that lacks the RGD integrin-binding motif: flexibility in aphthovirus receptor usage.

    J Virol 2000, 74:1641-1647. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  22. Fry EE, Lea SM, Jackson T, Newman JW, Ellard FM, Blakemore WE, Abu-Ghazaleh R, Samuel A, King AM, Stuart DI: The structure and function of a foot-and-mouth disease virus-oligosaccharide receptor complex.

    EMBO J 1999, 18:543-554. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  23. Jackson T, Ellard FM, Ghazaleh RA, Brookes SM, Blakemore WE, Corteyn AH, Stuart DI, Newman JW, King AM: Efficient infection of cells in culture by type O foot-and-mouth disease virus requires binding to cell surface heparan sulfate.

    J Virol 1996, 70:5282-5287. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  24. Sa-Carvalho D, Rieder E, Baxt B, Rodarte R, Tanuri A, Mason PW: Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle.

    J Virol 1997, 71:5115-5123. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  25. Duque H, LaRocco M, Golde WT, Baxt B: Interactions of foot-and-mouth disease virus with soluble bovine alphaVbeta3 and alphaVbeta6 integrins.

    J Virol 2004, 78:9773-9781. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  26. Colston E, Racaniello VR: Soluble receptor-resistant poliovirus mutants identify surface and internal capsid residues that control interaction with the cell receptor.

    EMBO J 1994, 13:5855-5862. PubMed Abstract | PubMed Central Full Text OpenURL

  27. Colston EM, Racaniello VR: Poliovirus variants selected on mutant receptor-expressing cells identify capsid residues that expand receptor recognition.

    J Virol 1995, 69:4823-4829. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  28. Monaghan P, Gold S, Simpson J, Zhang Z, Weinreb PH, Violette SM, Alexandersen S, Jackson T: The alpha(v)beta6 integrin receptor for Foot-and-mouth disease virus is expressed constitutively on the epithelial cells targeted in cattle.

    J Gen Virol 2005, 86:2769-2780. PubMed Abstract | Publisher Full Text OpenURL

  29. Swaney LM: A continuous bovine kidney cell line for routine assays of foot-and-mouth disease virus.

    Vet Microbiol 1988, 18:1-14. PubMed Abstract | Publisher Full Text OpenURL

  30. Weinacker A, Chen A, Agrez M, Cone RI, Nishimura S, Wayner E, Pytela R, Sheppard D: Role of the integrin alpha v beta 6 in cell attachment to fibronectin. Heterologous expression of intact and secreted forms of the receptor.

    J Biol Chem 1994, 269:6940-6948. PubMed Abstract | Publisher Full Text OpenURL

  31. Gianni T, Cerretani A, Dubois R, Salvioli S, Blystone SS, Rey F, Campadelli-Fiume G: Herpes simplex virus glycoproteins H/L bind to cells independently of {alpha}V{beta}3 integrin and inhibit virus entry, and their constitutive expression restricts infection.

    J Virol 2010, 84:4013-4025. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  32. Gianni T, Gatta V, Campadelli-Fiume G: {alpha}V{beta}3-integrin routes herpes simplex virus to an entry pathway dependent on cholesterol-rich lipid rafts and dynamin2.

    Proc Natl Acad Sci USA 2010, 107:22260-22265. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  33. Xu X, Nagarajan H, Lewis NE, Pan S, Cai Z, Liu X, Chen W, Xie M, Wang W, Hammond S, Andersen MR, Neff N, Passarelli B, Koh W, Fan HC, Wang J, Gui Y, Lee KH, Betenbaugh MJ, Quake SR, Famili I, Palsson BO, Wang J: The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line.

    Nat Biotechnol 2011, 29:735-741. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  34. Esko JD, Stewart TE, Taylor WH: Animal cell mutants defective in glycosaminoglycan biosynthesis.

    Proc Natl Acad Sci USA 1985, 82:3197-3201. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  35. Esko JD, Weinke JL, Taylor WH, Ekborg G, Roden L, Anantharamaiah G, Gawish A: Inhibition of chondroitin and heparan sulfate biosynthesis in Chinese hamster ovary cell mutants defective in galactosyltransferase I.

    J Biol Chem 1987, 262:12189-12195. PubMed Abstract | Publisher Full Text OpenURL

  36. Maree FF, Blignaut B, Aschenbrenner L, Burrage T, Rieder E: Analysis of SAT1 type foot-and-mouth disease virus capsid proteins: influence of receptor usage on the properties of virus particles.

    Virus Res 2011, 155:462-472. PubMed Abstract | Publisher Full Text OpenURL

  37. Maree FF, Blignaut B, de Beer TA, Visser N, Rieder EA: Mapping of amino acid residues responsible for adhesion of cell culture-adapted foot-and-mouth disease SAT type viruses.

    Virus Res 2010, 153:82-91. PubMed Abstract | Publisher Full Text OpenURL

  38. Lidholt K, Weinke JL, Kiser CS, Lugemwa FN, Bame KJ, Cheifetz S, Massague J, Lindahl U, Esko JD: A single mutation affects both N-acetylglucosaminyltransferase and glucuronosyltransferase activities in a Chinese hamster ovary cell mutant defective in heparan sulfate biosynthesis.

    Proc Natl Acad Sci USA 1992, 89:2267-2271. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  39. Esko JD, Rostand KS, Weinke JL: Tumor formation dependent on proteoglycan biosynthesis.

    Science 1988, 241:1092-1096. PubMed Abstract | Publisher Full Text OpenURL

  40. Stephens RS, Poteralski JM, Olinger L: Interaction of Chlamydia trachomatis with mammalian cells is independent of host cell surface heparan sulfate glycosaminoglycans.

    Infect Immun 2006, 74:1795-1799. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  41. Zhao QZ, Pacheco JM, Mason PW: Evaluation of genetically engineered derivatives of a Chinese strain of foot-and-mouth disease virus reveals a novel cell-binding site which functions in cell culture and in animals.

    J Virol 2003, 77:3269-3280. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  42. Johns HL, Berryman S, Monaghan P, Belsham GJ, Jackson T: A dominant-negative mutant of rab5 inhibits infection of cells by foot-and-mouth disease virus: implications for virus entry.

    J Virol 2009, 83:6247-6256. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  43. O'Donnell V, Larocco M, Baxt B: Heparan sulfate-binding foot-and-mouth disease virus enters cells via caveola-mediated endocytosis.

    J Virol 2008, 82:9075-9085. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  44. O'Donnell CD, Shukla D: A novel function of heparan sulfate in the regulation of cell-cell fusion.

    J Biol Chem 2009, 284:29654-29665. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  45. Neff S, Mason PW, Baxt B: High-efficiency utilization of the bovine integrin alpha(v) beta(3) as a receptor for foot-and-mouth disease virus is dependent on the bovine beta(3) subunit.

    J Virol 2000, 74:7298-7306. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  46. Dicara D, Burman A, Clark S, Berryman S, Howard MJ, Hart IR, Marshall JF, Jackson T: Foot-and-mouth disease virus forms a highly stable, EDTA-resistant complex with its principal receptor, integrin alphavbeta6: implications for infectiousness.

    J Virol 2008, 82:1537-1546. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  47. Domingo E, Escarmis C, Martinez MA, Martinez-Salas E, Mateu MG: Foot-and-mouth disease virus populations are quasispecies.

    Curr Top Microbiol Immunol 1992, 176:33-47. PubMed Abstract | Publisher Full Text OpenURL

  48. Mateu MG, Valero ML, Andreu D, Domingo E: Systematic replacement of amino acid residues within an Arg-Gly-Asp-containing loop of foot-and-mouth disease virus and effect on cell recognition.

    J Biol Chem 1996, 271:12814-12819. PubMed Abstract | Publisher Full Text OpenURL

  49. Rieder E, Baxt B, Mason PW: Animal-derived antigenic variants of foot-and-mouth disease virus type A12 have low affinity for cells in culture.

    J Virol 1994, 68:5296-5299. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  50. Nunez JI, Martin MJ, Piccone ME, Carrillo E, Palma EL, Dopazo J, Sobrino F: Identification of optimal regions for phylogenetic studies on VP1 gene of foot-and-mouth disease virus: analysis of types A and O Argentinean viruses.

    Vet Res 2001, 32:31-45. PubMed Abstract | Publisher Full Text OpenURL

  51. Weddell GN, Yansura DG, Dowbenko DJ, Hoatlin ME, Grubman MJ, Moore DM, Kleid DG: Sequence variation in the gene for the immunogenic capsid protein VP1 of foot-and-mouth disease virus type A.

    Proc Natl Acad Sci USA 1985, 82:2618-2622. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  52. Logan D, Abu-Ghazaleh R, Blakemore W, Curry S, Jackson T, King A, Lea S, Lewis R, Newman J, Parry N, et al.: Structure of a major immunogenic site on foot-and-mouth disease virus.

    Nature 1993, 362:566-568. PubMed Abstract | Publisher Full Text OpenURL

  53. Combet C, Jambon M, Deleage G, Geourjon C: Geno3D: automatic comparative molecular modelling of protein.

    Bioinformatics 2002, 18:213-214. PubMed Abstract | Publisher Full Text OpenURL

  54. Borca MV, Pacheco JM, Holinka LG, Carrillo C, Hartwig E, Garriga D, Kramer E, Rodriguez L, Piccone ME: Role of arginine-56 within the structural protein VP3 of foot-and-mouth disease virus (FMDV) O1 Campos in virus virulence.

    Virology 2011, 422:37-45. PubMed Abstract | Publisher Full Text OpenURL

  55. Ojosnegros S, Perales C, Mas A, Domingo E: Quasispecies as a matter of fact: Viruses and beyond.

    Virus Res 2011.

    In press

    OpenURL

  56. Wells VR, Plotch SJ, DeStefano JJ: Determination of the mutation rate of poliovirus RNA-dependent RNA polymerase.

    Virus Res 2001, 74:119-132. PubMed Abstract | Publisher Full Text OpenURL

  57. Li P, Lu Z, Bao H, Li D, King DP, Sun P, Bai X, Cao W, Gubbins S, Chen Y, Xie B, Guo J, Yin H, Liu Z: In-vitro and in-vivo phenotype of Asia1 foot-and-mouth disease viruses utilizing two non-RGD receptor recognition sites.

    BMC Microbiol 2011, 11:1-12. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL

  58. Gutierrez-Rivas M, Pulido MR, Baranowski E, Sobrino F, Saiz M: Tolerance to mutations in the foot-and-mouth disease virus integrin-binding RGD region is different in cultured cells and in vivo and depends on the capsid sequence context.

    J Gen Virol 2008, 89:2531-2539. PubMed Abstract | Publisher Full Text OpenURL

  59. Rieder E, Henry T, Duque H, Baxt B: Analysis of a foot-and-mouth disease virus type A24 isolate containing an SGD receptor recognition site in vitro and its pathogenesis in cattle.

    J Virol 2005, 79:12989-12998. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  60. Rieder E, Bunch T, Brown F, Mason PW: Genetically engineered foot-and-mouth disease viruses with poly(C) tracts of two nucleotides are virulent in mice.

    J Virol 1993, 67:5139-5145. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  61. Fry EE, Newman JW, Curry S, Najjam S, Jackson T, Blakemore W, Lea SM, Miller L, Burman A, King AM, Stuart DI: Structure of Foot-and-mouth disease virus serotype A10 61 alone and complexed with oligosaccharide receptor: receptor conservation in the face of antigenic variation.

    J Gen Virol 2005, 86:1909-1920. PubMed Abstract | Publisher Full Text OpenURL

  62. Guex N, Peitsch MC: SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling.

    Electrophoresis 1997, 18:2714-2723. PubMed Abstract | Publisher Full Text OpenURL

  63. Kaplan W, Littlejohn TG: Swiss-PDB Viewer (Deep View).

    Brief Bioinform 2001, 2:195-197. PubMed Abstract | Publisher Full Text OpenURL